<DOC>
	<DOCNO>NCT01787669</DOCNO>
	<brief_summary>The specific aim study test follow hypothesis : That switch treatment bevacizumab Ozurdex vice versa eye diabetic macular oedema incomplete response one therapy beneficial .</brief_summary>
	<brief_title>Trial Switching Between Intravitreal Bevacizumab ( Avastin® ) &amp; Intravitreal Dexamethasone ( Ozurdex™ ) Persistent Diabetic Macular Oedema</brief_title>
	<detailed_description>A Multicentre Clinical Trial Switching Between Intravitreal Bevacizumab ( Avastin® ) Intravitreal Dexamethasone ( Ozurdex™ ) Persistent Diabetic Macular Oedema ( SwitchDMO )</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Eyes Previously Treated bevacizumab : 1 . Diabetic macular oedema affect fovea persist despite ongoing , monthly intravitreal injection bevacizumab least 6 month , last 2 3 month prior screen visit . 2 . There must historical OCT available 14 week last bevacizumab injection retinal thickness &gt; 300 micron central 1mm subfield Spectral domain OCT show lack complete response bevacizumab . 3 . At screening , bevacizumab treat eye must DMO retinal thickness &gt; 300 micron central 1mm subfield Spectral domain OCT Eyes Previously Treated dexamethasone : 4 . Diabetic macular oedema affect fovea persist despite two dexamethasone implant 5 few month apart , last 58 month prior screen visit . 5 . There must historical OCT available 814 week last dexamethasone implant retinal thickness &gt; 300 micron central 1mm subfield Spectral domain OCT show lack complete response dexamethasone implant . 6 . At screening , dexamethasone treat eye must DMO retinal thickness &gt; 300 micron central 1mm subfield Spectral domain OCT 7 . Age &gt; = 18 year 8 . Diagnosis diabetes mellitus 9 . Best correct visual acuity 2078 letter ( approx 6/120 6/7.5 ) 10 . Previous macular laser treatment , investigator believe laser treatment unlikely helpful 11 . Intraocular pressure &lt; 22mmHg 12 . Women childbearing potential must negative urine pregnancy test screen visit prior treatment . A woman consider childbearing potential unless postmenopausal without menses 12 month surgically sterilise 13 . Written inform consent obtain . Treatment intravitreal triamcinolone acetonide ( IVTA ) within last 6 month peribulbar TA within last 3 month , anti vascular endothelial growth factor ( VEGF ) drug : ranibizumab aflibercept , within last 2 month . Cataract surgery within last 3 month Retinal laser treatment within last 3 month For eye switch Dexamethasone : Patient consider , judgement investigator , atrisk syphilis , tuberculosis potentially infective chorioretinopathies . Patients consider atrisk may assess investigator discretion reasonably exclude condition . Should condition exclude , patient may consider enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>diabetic macular oedema</keyword>
	<keyword>diabetic macular edema</keyword>
	<keyword>diabetic retinopathy</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>Ozurdex</keyword>
	<keyword>Avastin</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>DME</keyword>
	<keyword>DMO</keyword>
</DOC>